Hybrid lipid-polymer nanoplatform: A systematic review for targeted colorectal cancer therapy

Dave, Richa; Patel, Rashmin B.; Patel, Mrunali R.

doi:10.1016/j.eurpolymj.2023.111877

Cited by 5 publications

(1 citation statement)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te efcacy of anticancer drugs can be improved through the modifcation of CS, which leads to an increase in their accumulation, retention time, cytotoxicity, and cellular uptake by tumor cells [110]. Research conducted on various cell lines, including HT-29, HCT-116, HT-29, MCF-7, Caco-2, CT26, and SW480, has demonstrated a noteworthy reduction in cancer volume and substantial antitumor efcacy [111][112][113][114]. To summarize, using oral CS-based nanocarriers that are either conjugated with targeting ligands or therapeutic agents holds signifcant potential for the development of colon-targeted DDS that exhibits low toxicity levels and requires less monitoring during cancer therapy (Table 2).…”

Section: Colorectal Cancermentioning

confidence: 99%

Chitosan and Its Derivative-Based Nanoparticles in Gastrointestinal Cancers: Molecular Mechanisms of Action and Promising Anticancer Strategies

Shokati Eshkiki,

Mansouri,

Karamzadeh

et al. 2024

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Gastrointestinal cancers account for a significant health concern as the existing treatment modalities, such as surgery, chemotherapy, and radiation therapy, exhibit considerable drawbacks, including a high probability of recurrence, insufficient drug specificity, and severe adverse effects. Hence, novel therapeutic approaches and enhanced tissue-specific targeting are required. Nanomedicine is a field of medicine that uses nanoscale carriers for targeting and administering drugs or diagnostic agents to particular tissues. In the field of nanomedicine, chitosan nanoparticles are well-established delivery technologies used as polymeric carriers. Chitosan is a natural carbohydrate that is biocompatible, biodegradable, polycationic, and mucoadhesive. Chitosan has shown promise in the administration of chemotherapeutic drugs, gene therapy, and immunotherapy for the treatment of gastrointestinal cancers. The limited water solubility of chitosan is one of its major disadvantages as a drug delivery system. Thus, solubility may be increased by chemically treating chitosan. Chitosan derivatives improve the activity, selectivity, biocompatibility, and therapeutic dose reduction of anticancer drugs when used in hydrogel, emulsion, surfactant formulations, and nanoformulation. Chitosan and its derivatives have shown effectiveness in nanoparticle production and exhibit unique surface properties, enabling them to interact selectively with gastrointestinal tumors through both active and passive targeting mechanisms. This review focuses on the molecular signaling pathways of chitosan nanoparticles and their derivatives as potential anticancer agents. The potential of future chitosan applications in gastrointestinal cancers is additionally highlighted.

show abstract